Cargando…

1421. IV Brincidofovir (BCV): Pharmacokinetics (PK) and Safety of Multiple Ascending Doses (MAD) in Healthy Subjects

BACKGROUND: BCV is a lipid conjugated nucleotide analog that has shown rapid viral clearance with oral administration in patients with adenovirus infection, and improved survival in animal models of smallpox. Phase I single ascending dose evaluation of IV BCV demonstrated that 2 hour infusions of 10...

Descripción completa

Detalles Bibliográficos
Autores principales:	Naderer, Odin, Schuck, Virna, Morrison, Marion, Anderson, Maggie, Arumugham, Thangam, Dunn, John
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253859/ http://dx.doi.org/10.1093/ofid/ofy210.1252

Ejemplares similares

Pharmacokinetics (PK) and Safety of Intravenous (IV) Brincidofovir (BCV) in Healthy Adult Subjects
por: Wire, Mary Beth, et al.
Publicado: (2017)

1387. Phase I Study to Evaluate the Safety and Pharmacokinetics (PK) of Single and Multiple Ascending Doses (SAD/MAD) of Intravenous (IV) Minocycline in Healthy Adult Subjects
por: Cornely, Oliver A, et al.
Publicado: (2018)

Experimental reproduction of winter dysentery in lactating cows using BCV — comparison with BCV infection in milk-fed calves
por: Tråvén, M, et al.
Publicado: (2001)

Experimental Treatment of Ebola Virus Disease with Brincidofovir
por: Dunning, Jake, et al.
Publicado: (2016)

Base-Calling Algorithm with Vocabulary (BCV) Method for Analyzing Population Sequencing Chromatograms
por: Fantin, Yuri S., et al.
Publicado: (2013)

Pharmacokinetics and Efficacy of a Potential Smallpox Therapeutic, Brincidofovir, in a Lethal Monkeypox Virus Animal Model
por: Hutson, Christina L., et al.
Publicado: (2021)

The Role of Brincidofovir in Preparation for a Potential Smallpox Outbreak
por: Foster, Scott A., et al.
Publicado: (2017)

Rapid Virologic Response to Brincidofovir in Children with Disseminated Adenovirus Infection
por: Chan, Shuk Ying, et al.
Publicado: (2021)

Lack of effect of ezogabine/retigabine on the pharmacokinetics of digoxin in healthy individuals: results from a drug–drug interaction study
por: Tompson, Debra J, et al.
Publicado: (2014)

Correction for Hutson et al., “Pharmacokinetics and Efficacy of a Potential Smallpox Therapeutic, Brincidofovir, in a Lethal Monkeypox Virus Animal Model”
por: Hutson, Christina L., et al.
Publicado: (2021)

Draft Genome Sequence of New Vancomycin-Resistant Enterococcus faecium Sequence Type 1421
por: Leong, Kelvin W. C., et al.
Publicado: (2018)

1421. Microbiology and Resistance of Diabetic Foot Osteomyelitis in a Teaching Hospital in Santiago, Chile
por: Valenzuela, Pablo Tomas, et al.
Publicado: (2019)

Brincidofovir (CMX001) for the Treatment of Severe Adenoviral Pneumonia in Kidney Transplant Recipient
por: Sudhindra, Praveen, et al.
Publicado: (2019)

The Effect of Food and Formulation on the Pharmacokinetics, Safety, and Tolerability of GSK1322322 in Healthy Volunteers
por: Naderer, Odin, et al.
Publicado: (2015)

Ceftobiprole: pharmacokinetics and PK/PD profile
por: Azanza Perea, José Ramón, et al.
Publicado: (2019)

Comparison of bovine coronavirus (BCV) antigens: Monoclonal antibodies to the spike glycoprotein distinguish between vaccine and wild-type strains
por: Hussain, Khalid A., et al.
Publicado: (1991)

Genomic relationship between turkey and bovine enteric coronaviruses identified by hybridization with BCV or TCV specific cDNA probes
por: Verbeek, A., et al.
Publicado: (1991)

Brincidofovir Is Not a Substrate for the Human Organic Anion Transporter 1: A Mechanistic Explanation for the Lack of Nephrotoxicity Observed in Clinical Studies
por: Tippin, Timothy K., et al.
Publicado: (2016)

1321. Population Pharmacokinetic (PK) and Pharmacokinetic/Pharmacodynamic (PK/PD) Target Attainment Analyses for Dalbavancin in Pediatric Patients
por: Carrothers, Timothy J, et al.
Publicado: (2020)

1421. Assessing Serious Infections Common in Persons Who Inject Drugs in the United States and Tennessee
por: Lowry, Michael, et al.
Publicado: (2020)

1421. A 5-year Review of Mycobacterium abscessus Susceptibility in a Tertiary Hospital in Thailand
por: Phuensan, Pawat, et al.
Publicado: (2022)

Safety, Tolerability, and Pharmacokinetics (PK) of Posaconazole (POS) Intravenous (IV) Solution and Oral Powder for Suspension in Children With Neutropenia
por: Groll, Andreas H, et al.
Publicado: (2017)

Concerns about pharmacokinetic (PK) and pharmacokinetic-pharmacodynamic (PK-PD) studies in the new therapeutic area of COVID-19 infection
por: Venisse, Nicolas, et al.
Publicado: (2020)

1421. Spatial distribution of surface microbiota and resistance genes within and between rooms in an intensive care unit
por: Ziegler, Matthew J, et al.
Publicado: (2023)

Successful Treatment of Adenovirus Infection with Brincidofovir in an Immunocompromised Patient after Hematological Stem Cell Transplantation
por: Van Genechten, T., et al.
Publicado: (2020)

Brincidofovir is a robust replication inhibitor against African swine fever virus in vivo and in vitro
por: Guo, Shibang, et al.
Publicado: (2023)

Brincidofovir Use after Foscarnet Crystal Nephropathy in a Kidney Transplant Recipient with Multiresistant Cytomegalovirus Infection
por: Vial, Romain, et al.
Publicado: (2017)

1719. Pharmacokinetics (PK) of Oritavancin in Children: The ORKIDS Trial
por: Bradley, John, et al.
Publicado: (2018)

New Acaciin-Loaded Self-Assembled Nanofibers as M(Pro) Inhibitors Against BCV as a Surrogate Model for SARS-CoV-2
por: Mohamad, Soad A, et al.
Publicado: (2021)

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Oral Brincidofovir for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplantation
por: Marty, Francisco M., et al.
Publicado: (2018)

Discovery of MK-1421, a Potent, Selective sstr3 Antagonist, as a Development Candidate for Type 2 Diabetes
por: Shah, Shrenik K., et al.
Publicado: (2015)

P1421: THE EFFECT OF HEMATOPOIETIC STEM CELL TRANSPLANTATION ON CEREBRAL PERFUSION AND OXYGEN METABOLISM IN PATIENTS WITH SICKLE CELL DISEASE
por: Afzali-Hashemi, Liza, et al.
Publicado: (2023)

In vitro dynamic pharmacokinetic/pharmacodynamic(PK/PD) modeling and PK/PD cutoff of cefquinome against Haemophilus parasuis
por: Xiao, Xia, et al.
Publicado: (2015)

Analysis of Mutations in the Gene Encoding Cytomegalovirus DNA Polymerase in a Phase 2 Clinical Trial of Brincidofovir Prophylaxis
por: Lanier, E. Randall, et al.
Publicado: (2016)

Sensitivity of Human Mastadenovirus, the Causal Agent of Pharyngoconjunctival Fever, Epidemic Keratoconjunctivitis, and Hemorrhagic Cystitis in Immunocompromised Individuals, to Brincidofovir
por: Hanaoka, Nozomu, et al.
Publicado: (2022)

PK-DB: pharmacokinetics database for individualized and stratified computational modeling
por: Grzegorzewski, Jan, et al.
Publicado: (2020)

Pharmacodynamic Parameters of Pharmacokinetic/Pharmacodynamic (PK/PD) Integration Models
por: Zhang, Longfei, et al.
Publicado: (2022)

The rare translocation t(14;21)(q11;q22) detected in a Moroccan patient with T-cell acute lymphoblastic leukemia
por: Chebihi, Z. Takki, et al.
Publicado: (2018)

In vivo Pharmacokinetic and Pharmacodynamic (PK/PD) Modeling and Establishment of the PK/PD Cutoff of Florfenicol Against Pasteurella multocida in Ducks
por: Xiao, Xia, et al.
Publicado: (2021)

Oral Brincidofovir Therapy for Monkeypox Outbreak: A Focused Review on the Therapeutic Potential, Clinical Studies, Patent Literature, and Prospects
por: Imran, Mohd., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_h1g5q89n6t40ggmk9dst95k6ri